Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.
Zions Bancorporation is down 3% in trading today as WTI crude falls to just $48 per barrel (Brent crude is at $51), and there are serious concerns that it... Read More
Barron's has dealt a blow to the valuation of Facebook this week printing an article on Monday that claimed the company's stock may be vogue right now but doesn't... Read More
From Grant’s 2018 Interest Rate Observer which took place on October 9th 2018 in NYC All content will be posted at this link and in our Q3 letters archive... Read More
Fox Business Network’s (FBN) Senior Correspondent Charles Gasparino reports activist investor Carl Icahn does not own stakes in Twitter. Gasparino reported that people close to Icahn have confirmed to... Read More
FTSE RAFI™ Equity Income combines a smart beta approach (i.e., breaking the link between price and portfolio weight) with a stock selection process that melds the characteristics of dividend... Read More
The Securities and Exchange Commission’s two new pieces of rule-making proposals aimed at trimming risks in exchange-traded funds (ETFs) could have an “unintended consequence” of driving investors into less well-regulated... Read More
In a unanimous decision, the US Supreme Court today said police cannot search cellphones without a warrant during arrests, a major victory for privacy rights groups. The Supreme court... Read More
by Matthew Allen, swissinfo.ch November 11, 2013 - 12:12 Switzerland’s largest cantonal bank will now face the stiffest regulatory scrutiny after being officially named alongside UBS AG (NYSE:UBS) and Credit Suisse AG... Read More
The U.S. Patent and Trademark Office on Monday rejected an attempt by hedge fund manager Kyle Bass to challenge two patents relating to Acorda Therapeutics Inc.’s flagship multiple sclerosis... Read More
Proxy Access Bylaw Developments And Trends by Sullivan & Cromwell
Introduction
The significant success of shareholder proxy access proposals this year is likely to result in even more shareholder proposals for... Read More